表柔比星联合紫杉醇治疗三阴性乳腺癌的疗效观察

Efficacy of Epirubicin Plus Paclitaxel in the Treatment of Triple-negative Breast Cancer

目的：探讨表柔比星联合紫杉醇在三阴性乳腺癌治疗中的应用效果。方法：选取某院2011年4月-2014年10月收治的三阴性乳腺癌患者90例,随机分为对照组（单独采用表柔比星方案治疗）与观察组（采用表柔比星联合紫杉醇方案治疗）。结果：观察组患者治疗后肿瘤直径、癌细胞叉头框蛋白及乳腺癌易感基因水平明显优于对照组,且观察组治疗有效率为82.22%,高于对照组的64.44%;不良反应发生率为13.33%,低于对照组的35.56%,两组对比差异显著（P〈0.05）。结论：表柔比星联合紫杉醇治疗三阴性乳腺癌效果显著。

Objective To investigate the epirubicin plus paclitaxel application results in triple negative breast cancer. Methods： 90 cases with triple-negative breast cancer treated in a hospital from April 2011 to October 2014 were randomly divided into control group （alone epirubicin regimen） and observation group （using epirubicin plus paclitaxel regimen）. Results： After treatment , tumor size, cancer cell protein and breast cancer susceptibility gene level forkhead box of the observation group were significantly better than those of the control group and the observation group therapy effective rate 82.22% , higher than 64.44% in the control group; the incidence of adverse reactions rate of 13.33 percent,lower than 35.56 percent in the control group, a significant difference between two groups （P 〈 0.05）. Conclusion： Effect of epirubicin plus paclitaxel is remarkable in the treatment of triple-negative breast cancer.